SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Financials Shenzhen New Industries Biomedical Engineering Co., Ltd.
Equities
300832
CNE100003T39
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.08 CNY | +1.65% |
|
-0.65% | -10.38% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 54,455 | 34,652 | 39,416 | 61,443 | 55,063 | - | - |
| Enterprise Value (EV) 1 | 54,455 | 34,652 | 38,934 | 60,397 | 53,018 | 51,968 | 52,248 |
| P/E ratio | 55.5 x | 35.6 x | 29.7 x | 37.2 x | 26.7 x | 21.2 x | 17 x |
| Yield | - | 1.36% | 1.4% | 1.28% | 1.78% | 2.23% | 2.6% |
| Capitalization / Revenue | 24.8 x | 13.6 x | 12.9 x | 15.6 x | 11.2 x | 8.97 x | 7.27 x |
| EV / Revenue | 24.8 x | 13.6 x | 12.8 x | 15.4 x | 10.8 x | 8.46 x | 6.9 x |
| EV / EBITDA | 45.8 x | 27.8 x | 26.3 x | 31.3 x | 20.9 x | 16.6 x | 13.7 x |
| EV / FCF | - | - | 69.5 x | 55.1 x | 32.5 x | 26.6 x | 20.8 x |
| FCF Yield | - | - | 1.44% | 1.81% | 3.07% | 3.77% | 4.8% |
| Price to Book | 11.3 x | 6.17 x | 6.16 x | 8.14 x | 6.29 x | 5 x | 4.09 x |
| Nbr of stocks (in thousands) | 783,465 | 786,659 | 786,126 | 785,719 | 785,719 | - | - |
| Reference price 2 | 69.51 | 44.05 | 50.14 | 78.20 | 70.08 | 70.08 | 70.08 |
| Announcement Date | 30/03/21 | 21/04/22 | 06/04/23 | 11/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,195 | 2,545 | 3,047 | 3,930 | 4,918 | 6,140 | 7,575 |
| EBITDA 1 | 1,190 | 1,248 | 1,479 | 1,928 | 2,534 | 3,123 | 3,818 |
| EBIT 1 | 1,099 | 1,137 | 1,504 | 1,895 | 2,334 | 2,945 | 3,675 |
| Operating Margin | 50.05% | 44.69% | 49.35% | 48.23% | 47.46% | 47.96% | 48.52% |
| Earnings before Tax (EBT) 1 | 1,097 | 1,136 | 1,501 | 1,893 | 2,362 | 2,975 | 3,697 |
| Net income 1 | 939.1 | 973.7 | 1,328 | 1,654 | 2,064 | 2,594 | 3,231 |
| Net margin | 42.79% | 38.25% | 43.58% | 42.08% | 41.96% | 42.24% | 42.65% |
| EPS 2 | 1.252 | 1.239 | 1.689 | 2.104 | 2.627 | 3.301 | 4.112 |
| Free Cash Flow 1 | - | - | 559.8 | 1,096 | 1,630 | 1,957 | 2,508 |
| FCF margin | - | - | 18.37% | 27.9% | 33.14% | 31.87% | 33.11% |
| FCF Conversion (EBITDA) | - | - | 37.85% | 56.86% | 64.33% | 62.67% | 65.68% |
| FCF Conversion (Net income) | - | - | 42.16% | 66.29% | 78.98% | 75.45% | 77.62% |
| Dividend per Share 2 | - | 0.6000 | 0.7000 | 1.000 | 1.249 | 1.562 | 1.819 |
| Announcement Date | 30/03/21 | 21/04/22 | 06/04/23 | 11/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | - | 989.3 | 1,865 | - | 1,022 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | 459.8 | 865.5 | 501.4 | 528.5 | - | - | - | - | - | - |
| Operating Margin | - | 46.48% | 46.4% | - | 51.73% | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | 458.8 | 864.3 | 501.3 | 527.5 | - | - | - | - | - | - |
| Net income | 355.1 | 394.9 | 750 | - | - | - | - | - | - | - | - |
| Net margin | - | 39.92% | 40.21% | - | - | - | - | - | - | - | - |
| EPS 1 | 0.4517 | 0.5025 | 0.9542 | - | - | 0.5425 | 0.6300 | 0.7100 | 0.7400 | 0.7300 | 0.7900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 27/04/23 | 24/08/23 | 24/08/23 | 26/10/23 | 11/04/24 | 25/04/24 | - | - | - | - | - |
1CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 482 | 1,047 | 2,045 | 3,095 | 2,815 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 560 | 1,096 | 1,630 | 1,957 | 2,508 |
| ROE (net income / shareholders' equity) | 22.4% | 18.9% | 21.9% | 23.7% | 23.5% | 24.3% | 24.5% |
| ROA (Net income/ Total Assets) | 21.4% | 17% | 18.9% | 20.3% | 22% | 22.4% | 22.2% |
| Assets 1 | 4,382 | 5,721 | 7,015 | 8,142 | 9,381 | 11,593 | 14,532 |
| Book Value Per Share 2 | 6.130 | 7.130 | 8.140 | 9.600 | 11.10 | 14.00 | 17.20 |
| Cash Flow per Share 2 | 1.250 | 0.9800 | 1.220 | 1.810 | 2.860 | 2.920 | 3.750 |
| Capex 1 | 253 | 343 | 403 | 322 | 374 | 407 | 596 |
| Capex / Sales | 11.53% | 13.46% | 13.21% | 8.2% | 7.61% | 6.63% | 7.87% |
| Announcement Date | 30/03/21 | 21/04/22 | 06/04/23 | 11/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
70.08
CNY
Average target price
85.5
CNY
Spread / Average Target
+22.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.38% | 7.58B | |
| -10.04% | 11.22B | |
| +27.58% | 5.48B | |
| +2.04% | 5.38B | |
| -17.38% | 3.77B | |
| +8.12% | 2.6B | |
| -64.90% | 2.35B | |
| -9.04% | 2.25B | |
| +26.75% | 2.2B | |
| -12.53% | 1.7B |
- Stock Market
- Equities
- 300832 Stock
- Financials Shenzhen New Industries Biomedical Engineering Co., Ltd.
